Argatroban for prevention and treatment of thromboembolism in heparin-induced thrombocytopenia

Annals of Pharmacotherapy

Volumn 35, Issue 4, 2001, Pages 440-451

  Kondo, L Midori ^a   Wittkowsky, Ann K ^a,b   Wiggins, Barbara S ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

Argatroban; Heparin induced thrombocytopenia

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; ARGATROBAN; DALTEPARIN; DANAPAROID; DIGOXIN; ERYTHROMYCIN; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; LEPIRUDIN; LIDOCAINE; PARACETAMOL; THROMBIN INHIBITOR; WARFARIN;

ANGIOCARDIOGRAPHY; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CORONARY STENT; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG MONITORING; DRUG PROTEIN BINDING; DRUG STRUCTURE; GERIATRICS; HEART INFARCTION; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; LIVER FAILURE; OCCLUSIVE CEREBROVASCULAR DISEASE; PARTIAL THROMBOPLASTIN TIME; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; THROMBOCYTOPENIA; THROMBOEMBOLISM;

ANIMALS; ANTICOAGULANTS; ANTITHROMBINS; CLINICAL TRIALS; HEPARIN; HUMANS; PIPECOLIC ACIDS; THROMBOCYTOPENIA; THROMBOEMBOLISM;

EID: 0035096023     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.10301     Document Type: Article

References (39)

1. Antithrombin agents as anticoagulants and antithrombotics: Implications in drug development
2. Development of argatroban, a direct thrombin inhibitor, and its clinical application
3. Newer strategies for the treatment of heparin-induced thrombocytopenia
4. Comparison of the anticoagulant effects and safety of argatroban and heparin in healthy subjects
5. Novastan (brand of argatroban): A small-molecule, direct thrombin inhibitor
6. Argatroban: A synthetic thrombin inhibitor of low relative molecular mass
7. Clinical application of the synthetic thrombin inhibitor, argatroban (MD-805)
8. The pharmacokinetics and pharmacodynamics of argatroban: Effects of age, gender, and hepatic or renal dysfunction
9. Assessment of the potential pharmacokinetic and pharmacodynamic interaction between erythromycin and argatroban
10. The preclinical and clinical pharmacology of Novastan (argatroban): A small-molecule, direct thrombin inhibitor
11. Comparative studies on the biochemical and pharmacological properties of a major metabolite of argatroban (M1): Potential clinical implications
12. Argatroban provides effective and safe anticoagulation in patients with heparin-induced thrombocytopenia: A prospective historical controlled study
13. Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome
14. Clinical experience with combined treatment of thrombin inhibitors and GP IIb/IIIa inhibitors in patients with HIT
15. Thrombin inhibition in the acute phase of ischemic stroke using argatroban
16. Effect of the thrombin inhibitor argatroban in acute cerebral thrombosis
17. Effect of thrombin inhibition on patients with peripheral arterial obstructive disease: A multicenter clinical trial of argatroban
18. Results of a phase 2/3 trial of argatroban anticoagulation during PTCA of patients with heparin-induced thrombocytopenia
19. Report of successful use of argatroban as an alternative anticoagulant during coronary stent implantation in a patient with heparin-induced thrombocytopenia and thrombosis syndrome
20. A multi-center, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: Myocardial Infarction with Novastan and TPA (MINT) study
21. The first report of a successful carotid stent implant using argatroban anticoagulation in a patient with heparin- induced thrombocytopenia and thrombosis syndrome: A case report
22. Novastan anticoagulation during renal stent implant in a patient with heparin-induced thrombocytopenia
23. Treatment of heparin-induced thrombocytopenia by use of argatroban, a synthetic thrombin inhibitor
24. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris
25. Reactivation of unstable angina after discontinuation of heparin
26. Thrombin inhibitors in unstable angina: Rebound or continuation of angina after argatroban withdrawal
27. The international normalized ratio during concurrent warfarin and argatroban anticoagulation: Differential contributions of each agent and effects of the choice of thromboplastin used
28. Clinical effect of concurrent warfarin on the efficacy of argatroban therapy in heparin-induced thrombocytopenia
29. Combined administration of aspirin and a specific thrombin inhibitor in man
30. Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia
31. Limitations of conventional treatment options for heparin-induced thrombocytopenia
32. Heparin-induced thrombocytopenia (HIT): An overview of 230 patients treated with Orgaran (Org 10172)
33. Hirudins: Antithrombin anticoagulants
34. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators
35. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia. A prospective study
36. Coagulation laboratory testing in patients treated with argatroban